logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5667.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5667.produseast1
Showing 1 - 12 of 12 Items
Showing 1 - 12 of 12 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study

Gelé T, Atwine D, Baudin E, Muyindike W, Mworozi K,  et al.
2025-08-29 • Journal of Antimicrobial Chemotherapy
2025-08-29 • Journal of Antimicrobial Chemotherapy

BACKGROUND

Increasing rifampicin dosing is considered a potent strategy for shortening TB treatment ...

Journal Article
|
Commentary
Conference Material
|
Poster
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Video

Use of population pharmacokinetics to assess adherence to amodiaquine used for seasonal malaria chemoprevention

Coldiron ME
2020-05-13 • MSF Scientific Days International 2020
2020-05-13 • MSF Scientific Days International 2020
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Research & Publication Resources
|
Research Protocol

Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa

Chu WY, Verrest L, Younis BM, Musa AM, Mbui J,  et al.
2024-12-16 • Journal of Infectious Diseases
2024-12-16 • Journal of Infectious Diseases

Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to...

Optimizing nutrient supplementation among pregnant and reproductive age women in Kenya (VIRUTUBISHO)

Talbert A, Mwangome M, Berkley JA
2024-05-03 • MSF Paediatric Days 2024
2024-05-03 • MSF Paediatric Days 2024

Population pharmacokinetics of pediatric lopinavir/ritonavir oral pellets in children living with HIV in Africa

Chupradit S, Wamalwa DC, Maleche‐Obimbo E, Kekitiinwa AR, Mwanga‐Amumpaire J,  et al.
2024-05-01 • Clinical Pharmacology & Therapeutics
2024-05-01 • Clinical Pharmacology & Therapeutics
Antiretroviral therapy for children living with HIV (CLHIV) under 3 years of age commonly includes lopinavir/ritonavir (LPV/r). However, the original liquid LPV/r formulation has taste a...

Abacavir drug exposures in African children under 14 kg using paediatric solid fixed dose combinations according to World Health Organization weight bands

Chupradit S, Wamalwa DC, Maleche-Obimbo E, Kekitiinwa AR, Mwanga-Amumpaire J,  et al.
2023-10-05 • Journal of the Pediatric Infectious Diseases Society
2023-10-05 • Journal of the Pediatric Infectious Diseases Society
BACKGROUND
The pharmacokinetics of abacavir (ABC) in African children living with HIV (CLHIV) weighing < 14 kg and receiving pediatric fixed dose combinations (FDC) according to WHO ...

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis

Verrest L, Roseboom IC, Wasunna M, Mbui J, Njenga SN,  et al.
2023-09-20 • Journal of Antimicrobial Chemotherapy
2023-09-20 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated...

Adherence and population pharmacokinetic properties of amodiaquine when used for Seasonal Malaria Chemoprevention in African children

Ding J, Coldiron ME, Assao B, Guindo O, Blessborn D,  et al.
2019-10-25 • Clinical Pharmacology & Therapeutics
2019-10-25 • Clinical Pharmacology & Therapeutics
Poor adherence to seasonal malaria chemoprevention (SMC) might affect the protective effectiveness of SMC. Here, we evaluated the population pharmacokinetic properties of amodiaquine and...

Population pharmacokinetics and significant under-dosing of anti-tuberculosis medications in people with HIV and critical illness

Rao PS, Moore CC, Mbonde AA, Nuwagira E, Orikiriza P,  et al.
2021-06-18 • Antibiotics
2021-06-18 • Antibiotics
Critical illness from tuberculosis (TB) bloodstream infection results in a high case fatality rate for people living with human immunodeficiency virus (HIV). Critical illness can lead to...

Use of population pharmacokinetics to assess adherence to amodiaquine used for seasonal malaria chemoprevention

Coldiron ME
2020-05-13 • MSF Scientific Days International 2020
2020-05-13 • MSF Scientific Days International 2020

Use of population pharmacokinetics to assess adherence to amodiaquine used for seasonal malaria chemoprevention

Ding J, Coldiron ME, Assao B, Guindo O, Blessborn D,  et al.
2020-05-20 • MSF Scientific Days International 2020
2020-05-20 • MSF Scientific Days International 2020
INTRODUCTION
Seasonal malaria chemoprevention (SMC) has been widely implemented by MSF in the African Sahel. It consists of monthly courses of antimalarial drugs during the high-risk...

Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial

Nyang'wa BT, Kloprogge F, Moore DAJ, Bustinduy A, Motta I,  et al.
2021-09-06 • BMJ Open
2021-09-06 • BMJ Open
INTRODUCTION
Drug-resistant tuberculosis (TB) remains a global health threat, with little over 50% of patients successfully treated. Novel regimens like the ones being studied in the...